Hydrocele

Researchers are evaluating whether the combination of Disitamab Vedotin and Bicalutamide can treat advanced HER2-positive and androgen receptor AR-positive extramammary Paget disease of the scrotum. This Phase 2 clinical trial also aims to assess the safety of this drug combination in affected male patients. The study is sponsored by Fudan University and involves close monitoring of tumor responses during treatment using imaging techniques based on RECIST criteria. Participants receive Disitamab Vedotin every two weeks and take Bicalutamide daily throughout the treatment period. Follow-up continues until disease progression, intolerable side effects, withdrawal of consent, loss to follow-up, or death. The study measures include the objective response rate every six weeks up to 24 weeks, as well as progression-free survival and adverse events over approximately two years. During the trial, patients undergo clinical tumor imaging assessments and regular evaluations to monitor disease status and safety. Researchers track measurable lesions and skin lesions as per established criteria. The study involves ongoing safety monitoring and collects data on patient outcomes until the studys completion, with total participation lasting up to around two years.

Researchers are evaluating the combination of Disitamab Vedotin and Toripalimab to treat advanced HER2-positive extramammary Paget disease of the scrotum. This phase II clinical trial aims to determine if this combination reduces tumor size and delays disease progression, while also studying the safety and medical problems that may occur during treatment. Participants will receive intravenous infusions of Disitamab Vedotin at 2mgkg and Toripalimab at 3mgkg every 3 weeks. Treatment continues until the disease progresses, intolerable side effects occur, or other specified reasons arise. The study includes regular clinical tumor imaging and lesion measurements during treatment. Participants visit the clinic every 3 weeks for checkups and tests, including assessments of tumor response using RECIST criteria. The main outcome measured is the objective response rate every 6 weeks for up to 24 weeks. Secondary outcomes include progression-free survival and adverse events monitored over an average of 2 years. Follow-up continues until disease progression, withdrawal, loss to follow-up, or death.

This research focuses on patients with filarial infections, which are caused by parasitic worms transmitted through mosquito bites. The study aims to explore the immune systems response to these infections, including how people become susceptible, develop disease, and respond to treatment. The study includes patients diagnosed with or suspected of having infections such as Wuchereria bancrofti, Brugia malayi, Onchocerca volvulus, and Loa loa, among others. The research is observational and involves standard medical care without experimental diagnostics or treatments. Participants receive standard treatments like diethylcarbamazine or ivermectin depending on the infection type. Diagnostic tests include routine evaluations and may involve lung, skin, or heart assessments. Some patients might undergo skin biopsies or bronchoalveolar lavage if medically necessary. Additional research procedures include extra blood draws to study immune cells, urine collections, skin allergy tests, and leukapheresis to collect white blood cells in adults. During the study, participants undergo frequent and detailed follow-up evaluations including physical exams and blood tests. Researchers monitor immune responses and clinical outcomes over time, collecting blood and serum samples for laboratory studies. The main goal is to identify markers of infection, treatment responses, and immune regulation over a 10-year period. This long-term observation helps understand disease progression and treatment effects while ensuring patients receive optimal clinical care.